NDA 210605. Not in Drugs@FDA, which lists approved applications only; FDA's complete response letters name it.
As of Nov 16, 2026, NDA 210605 (Insulin glargine) is not in Drugs@FDA, which lists approved applications; FDA has published 2 complete response letters for it.
| Aug 28, 2019 | Insulin glargineFacility Inspections Major Deficiencies | Approved |
| May 17, 2018 | Insulin glargineClinical-Related Major Deficiencies, Product Quality-Related Major Deficiencies, Human Factors-Related Major Deficiencies | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters